Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial

AUTHORS

Huang Y , Hejazi NS , Blette B , Carpp LN , Benkeser D , Montefiori DC , McDermott AB , Fong Y , Janes HE , Deng W , Zhou H , Houchens CR , Martins K , Jayashankar L , Flach B , Lin BC , O'Connell S , McDanal C , Eaton A , Sarzotti-Kelsoe M , Lu Y , Yu C , Kenny A , Carone M , Huynh C , Miller J , El Sahly HM , Baden LR , Jackson LA , Campbell TB , Clark J , Andrasik MP , Kublin JG , Corey L , Neuzil KM , Pajon R , Follmann D , Donis RO , Koup RA , Gilbert PB , On Behalf Of The Immune Assays , Moderna Inc , Coronavirus Vaccine Prevention Network CoVPN/Coronavirus Efficacy Cove , United States Government Usg/CoVPN Biostatistics Teams , . Viruses. 2023 9 29; 15(10).

PMID: 37896806 [PubMed].

ABSTRACT

The COVE trial randomized participants to receive two doses of mRNA-1273 vaccine or placebo on Days 1 and 29 (D1, D29). Anti-SARS-CoV-2 Spike IgG binding antibodies (bAbs), anti-receptor binding domain IgG bAbs, 50% inhibitory dilution neutralizing antibody (nAb) titers, and 80% inhibitory dilution nAb titers were measured at D29 and D57. We assessed these markers as correlates of protection (CoPs) against COVID-19 using stochastic interventional vaccine efficacy (SVE) analysis and principal surrogate (PS) analysis, frameworks not used in our previous COVE immune correlates analyses. By SVE analysis, hypothetical shifts of the D57 Spike IgG distribution from a geometric mean concentration (GMC) of 2737 binding antibody units (BAU)/mL (estimated vaccine efficacy (VE): 92.9% (95% CI: 91.7%, 93.9%)) to 274 BAU/mL or to 27,368 BAU/mL resulted in an overall estimated VE of 84.2% (79.0%, 88.1%) and 97.6% (97.4%, 97.7%), respectively. By binary marker PS analysis of Low and High subgroups (cut-point: 2094 BAU/mL), the ignorance interval (IGI) and estimated uncertainty interval (EUI) for VE were [85%, 90%] and (78%, 93%) for Low compared to [95%, 96%] and (92%, 97%) for High. By continuous marker PS analysis, the IGI and 95% EUI for VE at the 2.5th percentile (519.4 BAU/mL) vs. at the 97.5th percentile (9262.9 BAU/mL) of D57 Spike IgG concentration were [92.6%, 93.4%] and (89.2%, 95.7%) vs. [94.3%, 94.6%] and (89.7%, 97.0%). Results were similar for other D29 and D57 markers. Thus, the SVE and PS analyses additionally support all four markers at both time points as CoPs.

Tags: 2023 Alumni Publications